ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.460
+0.120 (2.76%)
At close: Mar 27, 2026

HKG:1541 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
154.2974.150.390.545.07
Other Revenue
-5.397.315.158.74
154.2979.547.75.6913.81
Revenue Growth (YoY)
93.99%933.61%35.24%-58.79%-
Cost of Revenue
1.11----
Gross Profit
153.1879.547.75.6913.81
Selling, General & Admin
53.9464.8280.4292.848.32
Research & Development
322.28322.76291.94277.35175.95
Operating Expenses
376.22387.58372.37370.14224.27
Operating Income
-223.04-308.04-364.67-364.45-210.47
Interest Expense
-5.3-3.45-1.52-0.79-0.89
Interest & Investment Income
-6.3810.89.511.64
Currency Exchange Gain (Loss)
-1.790.126.11-9.13
Other Non Operating Income (Expenses)
9.08-0.02-25.92-73.27-514.83
EBT Excluding Unusual Items
-219.26-303.34-381.22-402.89-733.67
Gain (Loss) on Sale of Investments
-14.151.76--
Gain (Loss) on Sale of Assets
----0.56
Asset Writedown
--27.4---
Other Unusual Items
----0.17
Pretax Income
-219.26-316.59-379.46-402.89-732.95
Income Tax Expense
0.03----
Earnings From Continuing Operations
-219.29-316.59-379.46-402.89-732.95
Minority Interest in Earnings
0.710.74---
Net Income
-218.58-315.86-379.46-402.89-732.95
Net Income to Common
-218.58-315.86-379.46-402.89-732.95
Shares Outstanding (Basic)
41237736233286
Shares Outstanding (Diluted)
41237736233286
Shares Change (YoY)
9.35%4.24%9.05%284.99%-
EPS (Basic)
-0.53-0.84-1.05-1.21-8.50
EPS (Diluted)
-0.53-0.84-1.05-1.21-8.50
Free Cash Flow
--138.44-370.25-261.93-231.24
Free Cash Flow Per Share
--0.37-1.02-0.79-2.68
Gross Margin
99.28%100.00%100.00%100.00%100.00%
Operating Margin
-144.55%-387.30%-4739.09%-6405.13%-1524.23%
Profit Margin
-141.66%-397.12%-4931.24%-7080.74%-5308.15%
Free Cash Flow Margin
--174.06%-4811.50%-4603.41%-1674.69%
EBITDA
-212.76-297.77-352.26-352.54-202.69
EBITDA Margin
-137.89%----
D&A For EBITDA
10.2810.2812.4111.917.77
EBIT
-223.04-308.04-364.67-364.45-210.47
EBIT Margin
-144.55%----
Source: S&P Global Market Intelligence. Standard template. Financial Sources.